Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
connexin 40 CRISPR/Cas9 KO Plasmid (h): sc-401031
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- connexin 40 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the connexin 40 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: connexin 40 Antibody (B-3): sc-365107
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
connexin 40 CRISPR/Cas9 KO Plasmid (h) | sc-401031 | 20 µg | $397.00 |
Overview
GJA5 encodes connexin 40 (Cx40), a gap junction protein that assembles into intercellular channels enabling direct passage of ions and small metabolites between neighboring cells. Cx40-mediated coupling supports rapid electrical conduction and coordinated signaling, particularly in the cardiac atria and specialized conduction system, and also contributes to endothelial communication that shapes vascular tone and remodeling. Through regulation of cell–cell connectivity and impulse propagation, altered GJA5 function is linked to arrhythmia-related phenotypes, including atrial conduction abnormalities, and has been studied in the context of congenital cardiac defects and vascular dysregulation.
connexin 40 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GJA5 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GJA5 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GJA5 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish connexin 40 protein expression.
This CRISPR knockout system enables efficient generation of GJA5-deficient cell models for investigation of connexin 40 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GJA5 exon(s) critical for connexin 40 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GJA5 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by connexin 40 CRISPR/Cas9 KO Plasmid (h) and connexin 40 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GJA5 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by connexin 40 HDR Plasmid (h) and connexin 40 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GJA5 homology arms to support homology-directed repair at defined GJA5 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.